The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Consolidative radiotherapy for metastatic urothelial bladder cancer patients without progression and with no more than three residual metastatic lesions following first line systemic therapy: A prospective randomized comparative phase II trial (BLAD RAD01/GETUG-AFU V07).
 
Jonathan Khalifa
Honoraria - AstraZeneca; Ipsen; MSD
Consulting or Advisory Role - AstraZeneca; MSD
 
Damien Pouessel
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Mathieu Roumiguie
No Relationships to Disclose
 
Paul Sargos
No Relationships to Disclose
 
Genevieve Loos
No Relationships to Disclose
 
Ulrike Schick
No Relationships to Disclose
 
Naji Salem
No Relationships to Disclose
 
Nathalie Mesgouez-Nebout
No Relationships to Disclose
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Christophe Hennequin
No Relationships to Disclose
 
Emmanuel Meyer
No Relationships to Disclose
 
Pierre Blanchard
No Relationships to Disclose
 
Valentine Guimas
No Relationships to Disclose
 
Laurent Votron
No Relationships to Disclose
 
Pierre Graff-Cailleaud
No Relationships to Disclose
 
Gilles Crehange
No Relationships to Disclose
 
Muriel Mounier
No Relationships to Disclose
 
Angélique Massoubre
No Relationships to Disclose
 
Leonor Chaltiel
No Relationships to Disclose
 
Thomas Filleron
Consulting or Advisory Role - Cellectis (Inst)
Research Funding - Bristol Myers Squibb Foundation (Inst); Bristol Myers Squibb Foundation (Inst)